Will Bitcoin Or Dogecoin Grow More By 2022?

Every week, Benzinga conducts a survey to collect sentiment on what traders are most excited about, interested in or thinking about as they manage and build their personal portfolios. This week we posed the following question to Benzinga visitors on two of the world’s most popular cryptocurrencies:

Every week, Benzinga conducts a survey to collect sentiment on what traders are most excited about, interested in or thinking about as they manage and build their personal portfolios.

This week we posed the following question to Benzinga visitors on two of the world’s most popular cryptocurrencies:

Over the next year, which cryptocurrency will have the largest percentage gain? 

Here are the full results from this week’s survey:

  • Bitcoin: 12.6%
  • Dogecoin: 87.4%

This sentiment study was conducted as Bitcoin (CRYPTO: BTC) and Dogecoin (CRYPTO: DOGE) are both at or near new all-time highs.

At the time of publication, Bitcoin was trading at around $56,000 and Dogecoin $0.33. 

See Also: Is Bitcoin A Good Investment? and How To Buy Dogecoin.

Other Ways To Play Cryptocurrency: If holding crypto directly isn’t for you, here are eight stocks to play Bitcoin’s tear in 2021.

There are no stocks with exposure to Dogecoin. That is unless Elon Musk’s Tesla Inc (NASDAQ:TSLA) buys some of the Shiba Inu-based cryptocurrency as the company recently did with Bitcoin.

This survey was conducted by Benzinga in April 2021 and included the responses of a diverse population of adults 18 or older.

Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from over 1,000 adults.

Image: missionisgreat via Twitter

Total
0
Shares
Related Posts
Read More

Mesoblast Announced Remestemcel-L Improves Survival of Children With Biomarkers for Highest Mortality in Steroid Refractory Acute GVHD

Mesoblast Limited (Nasdaq: MESO) announced that results published in the latest issue of the peer-reviewed journal Bone Marrow Transplantation1 showed that children with steroid-refractory acute graft versus host disease (SR-aGVHD) and biomarkers predictive for highest mortality had 64% survival when treated with remestemcel-L

MESO